Neon Therapeutics
2013
FOUNDED
PUBLIC
STATUS
81-90
EMPLOYEES
NTGN
STOCK SYMBOL
$5.57
SHARE PRICE
(As of Friday Closing)
Description
Developer of neoantigen-targeted therapies designed to treat cancer by directing the immune system towards neoantigens. The company develops next-generation vaccines and T cell therapies targeting both personalized and shared neoantigens thus significantly improving the lives of patients.
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 40 Erie Street
- Suite 110
- Cambridge, MA 02139
- United States
+1 (617) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Neon Therapeutics’s full profile, request a free trial.
Neon Therapeutics Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $5.50 - $15.00 | $156M | $5.50 | -$6.23 | 161K | 28.3M |
Neon Therapeutics Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|
| Enterprise Value | 103,072 | ||
| Revenue | 0 | ||
| EBITDA | (68,254) | (47,185) | (27,022) |
| Net Income | (68,287) | (47,536) | (27,433) |
| Total Assets | 132,579 | 90,493 | 95,261 |
| Total Debt | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Neon Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Neon Therapeutics‘s full profile, request access.
Request full access to PitchBookNeon Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Neon Therapeutics‘s full profile, request access.
Request full access to PitchBookNeon Therapeutics Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Neon Therapeutics‘s full profile, request access.
Request full access to PitchBookNeon Therapeutics Executive Team (16)
3 Former Executives
You’re viewing 5 of 16 executives. Get the full list »Neon Therapeutics Board Members (8)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Cary Pfeffer MD | Third Rock Ventures | Chairman | 000 0000 | |
| Eric Lander Ph.D | Neon Therapeutics | Scientific Partner & Board Member | 000 0000 | |
| Hugh O'Dowd | Neon Therapeutics | Chief Executive Officer, President & Board Member | 000 0000 | |
| Julian Adams Ph.D | Clal Biotechnology Industries | Board Member | 000 0000 | |
| Meryl Zausner | Self | Board Member | 000 0000 |